New Advances in Micrornas in Diagnosing Chronic Diffuse Liver Disease in Rheumatoid Arthritis

Abstract

At present, multidisciplinary and multifactorial problems that have arisen and are developing at the intersection of several medical specialties are becoming particularly complex. One of these tasks is to study the features of diagnosis and treatment of rheumatic diseases in patients with chronic diffuse liver disease (CDD), especially chronic viral hepatitis (CHD), HAI and fatty liver (hepatic steatosis - SP). More precisely, liver damage in rheumatoid arthritis (RA) can be associated with toxic lesions caused by various drugs, primary (in autoimmune hepatitis - AIH) or secondary (against the background of diffuse connective tissue diseases), immunological and viral damage. This, in turn, requires the exclusion of secondary conditions before assessing pathological conditions in the liver. For early diagnosis of liver damage in RA patients, it is necessary to conduct regular examinations to assess the functional and organic state of the liver. In addition, it is very important to correctly and fully collect anamnestic data, to choose the right methods of clinical and laboratory examination. According to the literature, the use of determination of microRNA expression as a molecular diagnostic marker in this category of patients may prove to be highly effective in addressing these complications. Despite a lot of research, there is still no clear opinion on the use of treatments for patients with RA and liver disease. If it is possible to clarify the etiology and pathogenesis of liver damage in RA depending on the expression of microRNAs or to stratify risk groups for liver damage in RA by these biomarkers, it will be possible to achieve some progress in the treatment of these comorbid pathologies. The following literature review comprehensively discusses these problems and their modern solutions